Table 2: Antimicrobial activity of the Bacillus subtilis 534 cultural liquid (CL) against clinical isolates of Staphylococcus spp.
| Species, clinical isolates | Growth inhibition zones of CL, mm | The susceptibility/resistance of clinical isolates against 22 medical antibiotics* | |||
| R | I | S | Details:** | ||
| S. aureus 2476 | 0 | 3 | 0 | 18 | 3R: P, AM, LVX |
| S. capitis sbsp. urealyticus 1133 | 17 | 2 | 0 | 20 | 2R: P, AM |
| S. epidermidis 2480 | 0 | 16 | 0 | 6 | 6S: DAP, E, RA, SYN, TE, VA |
| S. epidermidis 2432 | 0 | 16 | 0 | 6 | 6S: DAP, E, RA, SYN, TE, VA |
| S. epidermidis 2624 | 25 | 15 | 0 | 5 | 5S: DAP, LZD, RA, SYN, VA |
| S. epidermidis 2688 | 0 | 16 | 0 | 4 | 4S: DAP, RA, TE, VA |
| S. epidermidis 1217 | (17)*** | 11 | 1 | 10 | 10S: C, CC, DAP, LZD, OX, RA, SYN, TE, SXT, VA1I: MXF |
| S. epidermidis 1259 | 0 | 12 | 0 | 10 | 10S: C, CC, DAP, LZD, MXF, RA, SYN, TE, SXT, VA |
| S. epidermidis 1306 | 0 | 6 | 0 | 16 | 6R: AM, E, LVX, P, TE, SXT |
| S. epidermidis 1319 | 0 | 3 | 1 | 18 | 3R: AM, E, P 1I: C |
| S. epidermidis 1401 | 0 | 14 | 1 | 7 | 7S: C, CC, DAP, LZD, RA, SYN, VA 1I: MXF |
| S. epidermidis 1109 | 0 | 11 | 0 | 10 | 10S: C, CC, DAP, LZD, MXF, RA, SYN, TE, SXT, VA |
| S. haemolyticus 4126 | 0 | 17 | 0 | 5 | 5S: DAP, RA, SYN, SXT, VA |
| S. hominis sbsp. Novobiosepticus 4221 | 0 | 14 | 0 | 8 | 8S: SAM, DAP, MXF, OX, RA, SYN, SXT, VA |
| S. xylosus 1298 | 0 | 15 | 0 | 6 | 6S: C, GM, LVX, MXF, TE, SXT |
*Antibiotics: AM: Ampicillin; AN: Amikacin; ATM: Aztreonam; C: Chloramphenicol; CC: Clindamycin; DAP: Daptomycin; E: Erythromycin; GM: Gentamicin; IPM: Imipenem; LZD: Linezolid; LVX: Levofloxacin; MEM: Meropenem; MXF: Moxifloxacin; NN: Tobramycin; OX: Oxacillin; P: Penicillin; RA: Rifampin; SAM: Ampicillin/Sulbactam; SXT: Trimethoprim/Sulfamethoxazole; SYN: Synercid; TE: Tetracyclin; VA: Vancomycin.
**R: Resistance; I: Intermediate susceptibility; S: Susceptibility.
***Growth oppression.